VYNE Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDVYNE Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 81), indicating clear outperformance against the broad market. Earnings growth of 58% provides fundamental context to the price action. Investors should exercise caution due to high volatility (116% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.65 | +2.16% | ABOVE |
| 50 SMA | $0.66 | +1.15% | ABOVE |
| 100 SMA | $0.63 | +5.87% | ABOVE |
| 150 SMA | $0.59 | +12.62% | ABOVE |
| 200 SMA | $0.53 | +25.09% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VYNE in an uptrend right now?
VYNE has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, VYNE is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is VYNE overbought or oversold?
VYNE's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is VYNE outperforming the market?
VYNE has a Relative Strength (RS) Rating of 81 out of 99. Yes, VYNE is a market leader, outperforming 81% of all stocks over the past 12 months.
Where is VYNE in its 52-week range?
VYNE is trading at $0.67, which is 42% of its 52-week high ($1.60) and 29% above its 52-week low ($0.28).
How volatile is VYNE?
VYNE has a Beta of 0.46 and 52-week volatility of 116%. It's less volatile than the S&P 500 - generally more stable.